

TARO PHARMACEUTICAL INDUSTRIES LTD  
Form SC 13D/A  
October 06, 2006  
CUSIP No. M8737E108

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

Taro Pharmaceutical Industries Ltd.

(Name of Issuer)

Ordinary Shares, NIS .0001 par value per share

(Title of Class of Securities)

M8737E108

(CUSIP Number)

Barbara J. Green

Vice President, Deputy General Counsel and Secretary

Franklin Resources, Inc.

One Franklin Parkway

San Mateo, CA 94403-1906

(650) 312-3000

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

October 5, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

1. NAMES OF REPORTING PERSONS.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).

Templeton Asset Management Ltd.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. SOURCE OF FUNDS

See Item 3

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEMS 2(d) OR 2(e)

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Singapore

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

3,344,380 (See Item 5)

8. SHARED VOTING POWER

None (See Item 5)

9. SOLE DISPOSITIVE POWER

3,344,380 (See Item 5)

10. SHARED DISPOSITIVE POWER

None (See Item 5)

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,344,380

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

CERTAIN SHARES [            ]

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

11.5%

CUSIP No. M8737E108

14. TYPE OF REPORTING PERSON

IA (See Item 5)

4

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

1. NAMES OF REPORTING PERSONS.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).

Franklin Resources, Inc. (13-2670991)

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. SOURCE OF FUNDS

See Item 3

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEMS 2(d) OR 2(e)

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

None (See Item 5)

8. SHARED VOTING POWER

None (See Item 5)

9. SOLE DISPOSITIVE POWER

None (See Item 5)

10. SHARED DISPOSITIVE POWER

None (See Item 5)

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,424,359

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

CERTAIN SHARES [            ]

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

15.2%



CUSIP No. M8737E108

14. TYPE OF REPORTING PERSON

HC (See Item 5)

6

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

1. NAMES OF REPORTING PERSONS.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).

Charles B. Johnson

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) [  ]

(b) x

3. SEC USE ONLY

4. SOURCE OF FUNDS

See Item 3

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEMS 2(d) OR 2(e) [  ]

6. CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

None (See Item 5)

8. SHARED VOTING POWER

None (See Item 5)

9. SOLE DISPOSITIVE POWER

None (See Item 5)

10. SHARED DISPOSITIVE POWER

None (See Item 5)

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,424,359

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

CERTAIN SHARES [            ]

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

CUSIP No. M8737E108

15.2%

14. TYPE OF REPORTING PERSON

HC; IN (See Item 5)

8

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

1. NAMES OF REPORTING PERSONS.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).

Rupert H. Johnson, Jr.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. SOURCE OF FUNDS

See Item 3

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEMS 2(d) OR 2(e)

6. CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

None (See Item 5)

8. SHARED VOTING POWER

None (See Item 5)

9. SOLE DISPOSITIVE POWER

None (See Item 5)

10. SHARED DISPOSITIVE POWER

None (See Item 5)

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,424,359

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

CERTAIN SHARES [            ]

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

CUSIP No. M8737E108

15.2%

14. TYPE OF REPORTING PERSON

HC; IN (See Item 5)

10

## Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

This Amendment No. 1 amends and supplements the Schedule 13D originally filed by the reporting persons with the Securities and Exchange Commission on August 4, 2006 (the Original Schedule 13D ) (together with Amendment No. 1 to the Original Schedule 13D, collectively, the Schedule 13D ). Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.

### **Item 3. Source and Amount of Funds or Other Consideration**

The response set forth in Item 3 of the Original Schedule 13D is hereby amended by deleting the text of Item 3 in its entirety and replacing it with the following:

The securities reported herein were acquired with funds of approximately \$61.3 million (including brokerage commissions). All such funds were provided from investment capital of one or more open- or closed-end investment companies or other managed accounts which are managed by TAML, Franklin Templeton Portfolio Advisors, Inc. and Franklin Advisers, Inc. (the Investment Management Subsidiaries ), each of which is a direct or indirect, wholly-owned subsidiary of FRI.

### **Item 4. Purpose of Transaction**

The response set forth in Item 4 of the Original Schedule 13D is hereby amended by deleting the text of Item 4 in its entirety and replacing it with the following:

The Investment Management Subsidiaries purchased the Ordinary Shares for their investment management clients for the purpose of investment. All such purchases were made in the open market in the ordinary course of the Investment Management Subsidiaries' business. None of the Investment Management Subsidiaries, and none of any of the other reporting persons to this Schedule 13D, currently has any plans or proposals that relate to or would result in any of the actions described in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D, except as otherwise set forth herein. However, TAML is concerned with the effect on the value of its investment management clients' investment in the Issuer of the Issuer's failure to timely file its financial statements for the fiscal year ended December 31, 2005 and of the Staff Determination, received by the Issuer on July 19, 2006, from the Listing Qualifications Department of The Nasdaq Stock Market with regard to the possible delisting of the Ordinary Shares from The Nasdaq Global Select Market. The explanations publicly announced by the Issuer for its failure to file the financial statements did not allay these concerns. Accordingly, TAML, together with the other reporting persons hereto, determined to file this Schedule 13D to provide TAML flexibility in order to explore appropriate action it, alone or together with other shareholders in the Issuer, could take to better evaluate and ultimately rectify their concerns. Such actions may include engaging in discussions with the Issuer, members of its Board of Directors, its officers, shareholders and others.

The Investment Management Subsidiaries' investment management clients may in the future acquire additional shares of Ordinary Shares or other securities of the Issuer, in the





CUSIP No. M8737E108

open market, in privately-negotiated purchases or otherwise, and may also dispose of all or a portion of the Ordinary Shares owned by their investment management clients in one or more transactions. The Investment Management Subsidiaries have purchased and/or disposed of a portion of such Ordinary Shares and may continue to do so. Additionally, the Investment Management Subsidiaries' investment management clients reserve the right to exercise any and all of their respective rights as a stockholder of the Issuer in a manner consistent with their equity interests and reserve the right from time to time to formulate plans or proposals regarding the Issuer or any of its securities, including without limitation to carry out any of the actions or transactions described in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D, to the extent deemed advisable by the Investment Management Subsidiaries.

#### **Item 5. Interest in Securities of the Issuer**

The response set forth in Item 5 of the Original Schedule 13D is hereby amended by deleting the text of Item 5 in its entirety and replacing it with the following:

(a-b) The 4,424,359 shares of Ordinary Shares of the Issuer (the "Securities"), representing 15.2% of the outstanding Ordinary Shares, are beneficially owned by one or more open- or closed-end investment companies or other managed accounts that are investment management clients of the Investment Management Subsidiaries (the "Investment Management Clients"). Investment management contracts grant to the Investment Management Subsidiaries all investment and/or voting power over the securities owned by such Investment Management Clients, except as otherwise disclosed below. Therefore, for purposes of Rule 13d-3 under the Act, the Investment Management Subsidiaries may be deemed to be the beneficial owners of the Securities.

Beneficial ownership by investment management subsidiaries and other affiliates of FRI is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34-39538 (January 12, 1998) relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by Franklin Mutual Advisers, LLC ("FMA"), an indirect wholly-owned investment management subsidiary of FRI, are exercised independently from FRI and from all other investment management subsidiaries of FRI (FRI, its affiliates and the investment management subsidiaries other than FMA are, collectively, "FRI affiliates"). Furthermore, internal policies and procedures of FMA and FRI establish informational barriers that prevent the flow between FMA and the FRI affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, FMA and the FRI affiliates report the securities over which they hold investment and voting power separately from each other for purposes of Section 13 of the Act.

The Principal Shareholders each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. FRI and the Principal Shareholders may be deemed to be, for purposes of Rule 13d-3 under the Act, the beneficial owners of

# Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

securities held by persons and entities for whom or for which FRI subsidiaries provide investment management services. The number of shares that may be deemed to be beneficially owned and the percentage of the class of which such shares are a part are reported in Items 11 and 13 of the cover pages for FRI and each of the Principal Shareholders. FRI, the Principal Shareholders and each of the Investment Management Subsidiaries disclaim any pecuniary interest in any of the Securities. In addition, the filing of this Schedule 13D on behalf of the Principal Shareholders, FRI and FRI affiliates, as applicable, should not be construed as an admission that any of them is, and each disclaims that it is, the beneficial owner, as defined in Rule 13d-3, of any of the Securities.

FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries believe that they are not a group within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the Securities held by any of them or by any persons or entities for whom or for which FRI subsidiaries provide investment management services.

The number of Ordinary Shares as to which each reporting person on this Schedule 13D and other Investment Management Subsidiaries has:

(i) Sole power to vote or to direct the vote of the Ordinary Shares:

Franklin Resources, Inc.:	0
Charles B. Johnson:	0
Rupert H. Johnson, Jr.:	0
Templeton Asset Management Ltd.:	3,344,380
Franklin Advisers, Inc.:	4,500
Franklin Templeton Portfolio Advisors, Inc. <sup>[1]</sup> :	1,075,479

(ii) Shared power to vote or to direct the vote of the Ordinary Shares:

0

(iii) Sole power to dispose or to direct the disposition of the Ordinary Shares:

Franklin Resources, Inc.:	0
Charles B. Johnson:	0
Rupert H. Johnson, Jr.:	0
Templeton Asset Management Ltd.:	3,344,380

---

Franklin Templeton Portfolio Advisors, Inc. ( FTPA ) may beneficially own these securities pursuant to various separately managed account investment management arrangements. Under these arrangements, underlying clients may, from time to time, delegate to FTPA the power to vote such securities. To the extent that FTPA has voting power over any such securities, it has sole voting power. To the extent that the underlying client retains voting power over any securities, FTPA disclaims any power to vote or direct the vote of such securities.



Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

Franklin Advisers, Inc.:	4,500
Franklin Templeton Portfolio Advisors, Inc.:	1,075,479

(iv) Shared power to dispose or to direct the disposition of the Ordinary Shares:

0

(c) Other than the transactions described in Exhibit B-1 of this statement, none of the reporting persons nor, to the best of their knowledge, any of the persons listed in Exhibit A, have effected any transactions in the Ordinary Shares during the 60-day period preceding the date this statement was filed.

(d) No person other than the respective Investment Management Clients is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities being reported herein.

(e) Not applicable.

**Item 7. Material to Be Filed as Exhibits**

The response set forth in Item 7 of the Original Schedule 13D is amended by deleting Exhibit B in its entirety and adding the following:

Exhibit B-1: Transactions in the Past Sixty Days

Exhibit C-1: Joint Filing Agreement, dated as of August 4, 2006 (incorporated by reference to Exhibit C of the Schedule 13D filed with the SEC on August 4, 2006)

Exhibit D-1: Powers of Attorney (incorporated by reference to Exhibit D of the Schedule 13D filed with the SEC on August 4, 2006)

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 6, 2006

FRANKLIN RESOURCES, INC.

CHARLES B. JOHNSON

RUPERT H. JOHNSON, JR.

By: /s/ Barbara J. Green

Barbara J. Green

Vice President, Deputy General Counsel and Secretary of Franklin Resources, Inc.

Attorney-in-Fact for Charles B. Johnson pursuant to a Power of Attorney attached to the Original Schedule 13D

Attorney-in-Fact for Rupert H. Johnson, Jr. pursuant to a Power of Attorney attached to the Original Schedule 13D

TEMPLETON ASSET MANAGEMENT

LTD.

By: /s/ Gregory E. McGowan

Gregory E. McGowan

Director of Templeton Asset Management Ltd.



CUSIP No. M8737E108

**EXHIBIT B-1****TRANSACTIONS IN THE PAST SIXTY DAYS**

Each of the transactions described below was a sale by TAML on behalf of its investment management clients of Ordinary Shares of the Issuer in the open market.

<b><u>Date of Transaction</u></b>	<b><u>Number of Shares</u></b>	<b><u>Price per Share</u></b>
		<b>(in U.S. Dollars)</b>
10/3/2006	1,200	12.9134
10/3/2006	3,200	12.9134
10/3/2006	8,000	12.9134
10/3/2006	8,800	12.9134
10/3/2006	2,000	12.9134
10/3/2006	30,400	12.9134
10/3/2006	602	12.9134
10/3/2006	16,800	12.9134
10/3/2006	1,200	12.9134
10/3/2006	4,800	12.9134
10/4/2006	2,000	12.5501
10/4/2006	6,000	12.5501
10/4/2006	15,200	12.5501
10/4/2006	17,200	12.5501
10/4/2006	2,800	12.5501
10/4/2006	62,000	12.5501
10/4/2006	800	12.5501
10/4/2006	33,600	12.5501
10/4/2006	1,200	12.5501
10/4/2006	9,200	12.5501
10/5/2006	2,500	12.2229
10/5/2006	8,000	12.2229
10/5/2006	20,500	12.2229
10/5/2006	23,000	12.2229
10/5/2006	4,000	12.2229
10/5/2006	82,500	12.2229
10/5/2006	1,000	12.2229
10/5/2006	44,500	12.2229
10/5/2006	1,500	12.2229
10/5/2006	12,500	12.2229

Each of the transactions described below was a purchase by FTPA on behalf of its investment management clients of Ordinary Shares of the Issuer in the open market.



**Date of Transaction**

**Number of Shares**

**Price per Share**

**(in U.S. Dollars)**

16

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/1/2006	247	13.4460
9/1/2006	25	13.4800
9/6/2006	88	14.5400
9/6/2006	105	14.6199
9/11/2006	61	14.0100
9/12/2006	39	14.2400
9/14/2006	44	13.9500
9/15/2006	140	13.6699
9/15/2006	10	13.6700
9/18/2006	727	13.6900
9/20/2006	18	13.5500
9/20/2006	70	13.5500
9/21/2006	174	13.4499
9/22/2006	36	13.0100
9/22/2006	14	13.0700
9/25/2006	75	12.9500
9/26/2006	83	13.5400
9/26/2006	522	13.4499
9/27/2006	21	13.5900
10/2/2006	95	12.8100
10/3/2006	158	12.9500
10/4/2006	62	12.5800
10/4/2006	14	12.5800

Each of the transactions described below was a sale by FTPA on behalf of its investment management clients of Ordinary Shares of the Issuer in the open market.

<u>Date of Transaction</u>	<u>Number of Shares</u>	<u>Price per Share</u>
		(in U.S. Dollars)
8/7/2006	17	12.9988
8/7/2006	31	13.0000
8/7/2006	12	13.0783
8/7/2006	43	13.0800
8/7/2006	18	13.0794
8/7/2006	21	13.0800
8/7/2006	11	13.0773
8/7/2006	48	13.0800
8/7/2006	32	13.0797
8/7/2006	27	13.0800
8/7/2006	12	12.9983
8/7/2006	34	13.0000
8/7/2006	12	12.9992
8/7/2006	1	13.0000



Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/7/2006	3	13.0733
8/7/2006	47	13.0800
8/7/2006	23	13.0796
8/7/2006	21	13.0800
8/7/2006	20	13.0785
8/7/2006	59	13.0800
8/7/2006	21	13.0795
8/7/2006	21	12.9986
8/7/2006	49	13.0000
8/7/2006	1	12.9800
8/7/2006	40	13.0000
8/7/2006	15	12.9993
8/7/2006	5	13.0000
8/7/2006	76	13.0796
8/7/2006	22	13.0800
8/7/2006	36	12.9994
8/7/2006	2	12.9950
8/7/2006	21	12.9995
8/7/2006	6	13.0000
8/7/2006	18	12.9994
8/7/2006	39	13.0000
8/7/2006	36	12.9994
8/7/2006	56	12.9995
8/7/2006	13	13.0769
8/7/2006	52	13.0800
8/7/2006	34	13.0797
8/7/2006	32	13.0800
8/7/2006	2	12.9900
8/7/2006	9	13.0000
8/7/2006	13	12.9992
8/7/2006	41	13.0000
8/7/2006	496	12.9996
8/7/2006	26	13.0785
8/7/2006	76	13.0800
8/7/2006	21	13.0795
8/7/2006	59	13.0797
8/7/2006	36	13.0800
8/7/2006	19	13.0795
8/7/2006	4	13.0800
8/7/2006	41	12.9990
8/7/2006	55	13.0000
8/8/2006	34	12.2594
8/8/2006	60	12.1793
8/8/2006	26	12.1800

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/9/2006	52	12.8692
8/9/2006	31	12.8697
8/9/2006	26	12.8700
8/9/2006	9	12.8667
8/9/2006	37	12.8700
8/9/2006	23	12.8696
8/9/2006	23	12.8700
8/10/2006	39	12.7495
8/10/2006	7	12.7500
8/10/2006	13	12.7492
8/10/2006	2	12.7500
8/10/2006	23	12.7496
8/10/2006	7	12.7500
8/10/2006	19	12.7495
8/10/2006	18	12.7500
8/10/2006	48	12.7600
8/10/2006	171	12.7596
8/10/2006	36	12.7042
8/10/2006	7	12.7057
8/10/2006	14	12.7050
8/10/2006	19	12.7053
8/10/2006	7	12.7057
8/10/2006	17	12.7053
8/10/2006	14	12.7050
8/10/2006	11	12.7055
8/10/2006	7	12.7057
8/10/2006	8	12.7050
8/10/2006	133	12.7051
8/10/2006	24	12.7050
8/10/2006	1	12.7100
8/10/2006	5	12.7060
8/10/2006	21	12.7052
8/10/2006	32	12.7050
8/10/2006	5	12.7060
8/11/2006	127	12.5096
8/11/2006	28	12.5593
8/11/2006	16	12.5600
8/11/2006	17	12.5594
8/11/2006	5	12.5600
8/11/2006	15	12.5593
8/11/2006	11	12.5600
8/11/2006	102	12.5095
8/11/2006	20	12.5100

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/11/2006	16	12.5094
8/11/2006	3	12.5100
8/11/2006	15	12.5280
8/11/2006	51	12.5282
8/11/2006	12	12.5283
8/11/2006	195	12.5282
8/11/2006	30	12.5283
8/11/2006	20	12.5285
8/11/2006	4	12.5275
8/11/2006	6	12.5283
8/11/2006	2	12.5300
8/11/2006	10	12.5280
8/11/2006	4	12.5275
8/11/2006	17	12.5182
8/11/2006	49	12.5200
8/11/2006	17	12.5194
8/11/2006	45	12.5198
8/11/2006	40	12.5200
8/14/2006	76	12.3996
8/14/2006	1	12.2000
8/14/2006	19	12.2100
8/14/2006	3	12.3500
8/14/2006	43	12.3600
8/14/2006	25	12.3596
8/14/2006	26	12.3600
8/14/2006	12	12.4992
8/14/2006	3	12.4967
8/14/2006	4	12.4975
8/14/2006	1	12.4900
8/14/2006	5	12.4980
8/14/2006	3	12.4967
8/14/2006	5	12.4980
8/14/2006	3	12.4967
8/14/2006	2	12.4950
8/14/2006	4	12.4975
8/14/2006	2	12.4950
8/14/2006	3	12.4967
8/14/2006	11	12.4991
8/14/2006	20	12.4995
8/14/2006	31	12.4994
8/14/2006	4	12.4975
8/14/2006	3	12.4967
8/14/2006	1	12.4900
8/14/2006	2	12.4950

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/14/2006	8	12.4988
8/14/2006	13	12.4992
8/14/2006	2	12.4950
8/14/2006	1	12.2200
8/14/2006	41	12.2500
8/14/2006	29	12.2497
8/14/2006	24	12.2500
8/14/2006	27	12.2093
8/15/2006	13	11.9777
8/15/2006	52	11.9800
8/15/2006	34	11.9797
8/15/2006	32	11.9800
8/15/2006	2	11.9700
8/15/2006	37	11.9800
8/15/2006	27	11.9796
8/15/2006	27	11.9800
8/15/2006	44	12.0395
8/15/2006	15	12.0487
8/15/2006	30	12.0500
8/15/2006	25	11.9788
8/15/2006	71	11.9800
8/15/2006	25	11.9796
8/15/2006	14	11.9800
8/15/2006	21	11.9795
8/15/2006	24	11.9800
8/15/2006	64	11.9797
8/15/2006	12	12.2483
8/15/2006	33	12.2500
8/15/2006	12	12.2492
8/15/2006	19	12.2495
8/15/2006	16	12.2500
8/16/2006	34	12.0894
8/16/2006	25	12.0896
8/16/2006	40	12.0898
8/16/2006	9	12.0900
8/16/2006	22	12.0895
8/16/2006	52	12.0900
8/16/2006	47	12.0898
8/16/2006	32	12.0897
8/16/2006	6	12.0650
8/16/2006	63	12.0700
8/16/2006	26	12.0696
8/16/2006	3	12.0700

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/16/2006	30	12.0697
8/16/2006	28	12.0700
8/16/2006	56	12.0696
8/16/2006	30	12.0700
8/16/2006	44	12.0698
8/16/2006	227	12.0697
8/17/2006	19	12.6395
8/17/2006	5	12.6400
8/17/2006	4	12.6450
8/17/2006	32	12.6500
8/17/2006	14	12.6493
8/17/2006	29	12.6497
8/17/2006	14	12.6500
8/17/2006	50	12.6600
8/17/2006	18	12.6594
8/17/2006	45	12.6596
8/17/2006	15	12.6600
8/17/2006	27	12.6393
8/18/2006	10	12.6000
8/18/2006	2	12.5950
8/18/2006	3	12.5933
8/18/2006	1	12.5900
8/18/2006	8	12.5950
8/18/2006	5	12.5940
8/18/2006	2	12.5950
8/18/2006	1	12.5900
8/18/2006	3	12.5933
8/18/2006	2	12.5950
8/18/2006	3	12.5933
8/18/2006	36	12.5950
8/18/2006	5	12.5940
8/18/2006	3	12.5933
8/18/2006	1	12.5900
8/18/2006	2	12.5950
8/18/2006	5	12.5940
8/18/2006	7	12.5943
8/18/2006	2	12.5950
8/18/2006	11	12.6673
8/18/2006	42	12.6700
8/18/2006	26	12.6696
8/18/2006	26	12.6700
8/18/2006	83	12.5952
8/18/2006	17	12.5947
8/18/2006	32	12.5950



Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/18/2006	43	12.5949
8/18/2006	17	12.5947
8/18/2006	40	12.5950
8/18/2006	17	12.5947
8/18/2006	13	12.5946
8/18/2006	25	12.5948
8/18/2006	17	12.5947
8/18/2006	20	12.5950
8/18/2006	305	12.5949
8/18/2006	58	12.5950
8/18/2006	1	12.5900
8/18/2006	13	12.5946
8/18/2006	48	12.5950
8/18/2006	72	12.5949
8/18/2006	15	12.5947
8/21/2006	50	13.0198
8/21/2006	7	13.0186
8/21/2006	58	13.0197
8/21/2006	8	13.0188
8/21/2006	4	13.0175
8/21/2006	17	13.0194
8/21/2006	26	13.0192
8/21/2006	4	13.0175
8/21/2006	128	13.0096
8/21/2006	16	13.0094
8/21/2006	41	13.0100
8/21/2006	18	13.0283
8/21/2006	53	13.0300
8/21/2006	19	13.0295
8/21/2006	47	13.0296
8/21/2006	45	13.0300
8/21/2006	10	13.0270
8/21/2006	39	13.0300
8/21/2006	25	13.0296
8/21/2006	23	13.0300
8/22/2006	123	13.6295
8/22/2006	96	13.2295
8/22/2006	31	13.2300
8/22/2006	171	13.5296
8/22/2006	25	13.5300
8/22/2006	19	13.5295
8/22/2006	3	13.5300
8/22/2006	95	13.2395

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/22/2006	30	13.2400
8/23/2006	88	13.1995
8/23/2006	33	13.2000
8/23/2006	128	13.2296
8/23/2006	22	13.3986
8/23/2006	64	13.4000
8/23/2006	76	13.3996
8/23/2006	31	13.4000
8/23/2006	53	13.1894
8/23/2006	40	13.1898
8/23/2006	30	13.1900
8/23/2006	4	13.1850
8/23/2006	39	13.1900
8/23/2006	17	13.1894
8/23/2006	14	13.1900
8/23/2006	39	13.2295
8/23/2006	12	13.2300
8/23/2006	45	13.2298
8/24/2006	12	13.9683
8/24/2006	13	13.9700
8/24/2006	15	13.9693
8/24/2006	4	13.9700
8/24/2006	13	13.9692
8/24/2006	28	13.9700
8/24/2006	15	13.9693
8/24/2006	49	14.0894
8/24/2006	12	13.9675
8/24/2006	41	13.9700
8/24/2006	31	13.9694
8/24/2006	23	13.9687
8/24/2006	14	13.9700
8/24/2006	12	13.9692
8/24/2006	5	13.9700
8/24/2006	11	13.9691
8/24/2006	25	13.9700
8/24/2006	23	13.9696
8/24/2006	29	13.9697
8/24/2006	47	13.5094
8/24/2006	38	13.5100
8/24/2006	103	13.5097
8/24/2006	10	14.0890
8/24/2006	5	14.0900
8/24/2006	7	14.0886
8/24/2006	3	14.0900

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/24/2006	1	14.0800
8/24/2006	16	14.0900
8/24/2006	14	13.9679
8/24/2006	35	13.9700
8/24/2006	11	14.0882
8/24/2006	13	14.0900
8/25/2006	48	14.5394
8/25/2006	37	14.5895
8/25/2006	7	14.5900
8/25/2006	12	14.5892
8/25/2006	2	14.5900
8/25/2006	19	14.5895
8/25/2006	7	14.5900
8/25/2006	17	14.5894
8/25/2006	14	14.5900
8/25/2006	11	14.5891
8/25/2006	185	14.5195
8/25/2006	56	14.1198
8/25/2006	11	14.1191
8/25/2006	18	14.1194
8/25/2006	3	14.1200
8/25/2006	31	14.1194
8/25/2006	24	14.1192
8/28/2006	18	14.0594
8/28/2006	1	14.1400
8/28/2006	74	14.1700
8/28/2006	19	14.1695
8/28/2006	11	14.1700
8/28/2006	30	14.0093
8/28/2006	16	14.0100
8/28/2006	11	14.0091
8/28/2006	47	14.0194
8/28/2006	5	14.0200
8/28/2006	27	14.0196
8/28/2006	26	14.0200
8/28/2006	30	14.1693
8/29/2006	22	13.2886
8/29/2006	62	13.2900
8/29/2006	22	13.2895
8/29/2006	55	13.2896
8/29/2006	31	13.2900
8/29/2006	19	13.2895
8/29/2006	3	13.2900

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

8/30/2006	14	12.7600
8/30/2006	11	12.7591
8/30/2006	14	12.7593
8/30/2006	52	12.7394
8/30/2006	197	12.7597
8/30/2006	40	12.7595
8/30/2006	62	12.7597
8/30/2006	14	12.7593
8/30/2006	104	12.7596
8/30/2006	40	12.7595
8/30/2006	95	12.7596
8/30/2006	40	12.7595
8/30/2006	17	12.7594
8/31/2006	4	13.0700
8/31/2006	14	13.0693
8/31/2006	44	13.0695
8/31/2006	7	13.0700
8/31/2006	21	13.0695
8/31/2006	4	13.0700
9/1/2006	14	13.4686
9/1/2006	42	13.4700
9/1/2006	15	13.4693
9/1/2006	37	13.4695
9/1/2006	21	13.4700
9/1/2006	12	13.4692
9/1/2006	2	13.4700
9/1/2006	11	13.1482
9/1/2006	17	13.1500
9/1/2006	14	13.1493
9/1/2006	6	13.1500
9/1/2006	14	13.1493
9/1/2006	60	13.1495
9/1/2006	31	13.1497
9/1/2006	26	13.1500
9/1/2006	16	13.1494
9/1/2006	4	13.1500
9/1/2006	17	13.4576
9/1/2006	56	13.4600
9/5/2006	174	14.5095
9/5/2006	39	14.5056
9/5/2006	7	14.5057
9/5/2006	12	14.5058
9/5/2006	2	14.5050
9/5/2006	24	14.5058

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/5/2006	7	14.5057
9/5/2006	6	14.5050
9/5/2006	5	14.4700
9/5/2006	8	14.4688
9/5/2006	2	14.4700
9/5/2006	7	14.4686
9/5/2006	2	14.4700
9/5/2006	16	14.5056
9/5/2006	47	14.5057
9/5/2006	19	14.5058
9/5/2006	49	14.5057
9/5/2006	16	14.5056
9/5/2006	94	14.5057
9/5/2006	27	14.5059
9/5/2006	90	14.5058
9/5/2006	30	14.5057
9/6/2006	35	14.5794
9/6/2006	29	14.5493
9/6/2006	6	14.5500
9/6/2006	24	14.5792
9/6/2006	3	14.5767
9/6/2006	11	14.5800
9/6/2006	16	14.5794
9/6/2006	11	14.5800
9/6/2006	4	14.5425
9/6/2006	28	14.5500
9/6/2006	18	14.5494
9/6/2006	25	14.5496
9/6/2006	24	14.5500
9/6/2006	13	14.5792
9/6/2006	5	14.5800
9/6/2006	26	14.5792
9/6/2006	144	14.5496
9/6/2006	5	14.5780
9/6/2006	9	14.5800
9/6/2006	8	14.5788
9/6/2006	10	14.5800
9/6/2006	13	14.5792
9/7/2006	4	14.6900
9/7/2006	34	14.6894
9/7/2006	2	14.6900
9/7/2006	51	14.6694
9/7/2006	12	14.6383

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/7/2006	33	14.6400
9/7/2006	11	14.6391
9/7/2006	30	14.6393
9/7/2006	15	14.6400
9/7/2006	11	14.6391
9/7/2006	238	14.6695
9/7/2006	1	14.6600
9/7/2006	21	14.6590
9/7/2006	3	14.6600
9/7/2006	30	14.6693
9/7/2006	24	14.6692
9/8/2006	230	14.2438
9/8/2006	16	14.0394
9/8/2006	23	14.4391
9/8/2006	40	14.4395
9/8/2006	17	14.4400
9/8/2006	11	14.4391
9/8/2006	6	13.9967
9/8/2006	13	14.0000
9/8/2006	13	13.9992
9/8/2006	29	13.9997
9/8/2006	26	14.0000
9/8/2006	3	14.0333
9/8/2006	37	14.0400
9/8/2006	19	14.1289
9/8/2006	19	14.1300
9/8/2006	4	14.0000
9/8/2006	12	13.9992
9/8/2006	13	14.0385
9/8/2006	14	14.0400
9/11/2006	12	14.0075
9/11/2006	35	14.0100
9/11/2006	12	14.0092
9/11/2006	31	14.0094
9/11/2006	29	14.0100
9/11/2006	9	14.0067
9/11/2006	35	14.0100
9/11/2006	24	14.0096
9/11/2006	21	14.0100
9/12/2006	29	14.2293
9/12/2006	17	14.2300
9/12/2006	16	14.2294
9/12/2006	4	14.2300
9/12/2006	12	14.2283

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/12/2006	16	14.2300
9/12/2006	7	14.2400
9/12/2006	376	14.2396
9/12/2006	29	14.2397
9/12/2006	1	14.2400
9/12/2006	15	14.2393
9/12/2006	18	14.2394
9/12/2006	205	14.2395
9/12/2006	369	14.2396
9/13/2006	24	13.9492
9/13/2006	22	13.8991
9/13/2006	11	13.9000
9/13/2006	14	13.8993
9/13/2006	1	13.9000
9/13/2006	55	13.8996
9/13/2006	2	13.8900
9/13/2006	17	13.9000
9/13/2006	15	13.8993
9/13/2006	50	13.9000
9/13/2006	23	13.8996
9/13/2006	87	13.9595
9/13/2006	27	13.9600
9/13/2006	44	13.8995
9/13/2006	9	13.9000
9/13/2006	14	13.8993
9/13/2006	3	13.9000
9/13/2006	23	13.8996
9/14/2006	81	13.9395
9/14/2006	2	13.9400
9/14/2006	26	13.9392
9/14/2006	16	13.9400
9/14/2006	14	13.9393
9/14/2006	5	13.9400
9/14/2006	13	13.9392
9/14/2006	29	13.9400
9/14/2006	26	13.9396
9/14/2006	13	13.9392
9/14/2006	13	13.9385
9/14/2006	32	13.9400
9/14/2006	18	13.9289
9/14/2006	16	13.9300
9/14/2006	21	13.9290
9/14/2006	15	13.9300

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/14/2006	4	13.9525
9/14/2006	21	13.9600
9/14/2006	23	13.9596
9/14/2006	33	13.9597
9/14/2006	29	13.9600
9/14/2006	8	13.9675
9/14/2006	28	13.9700
9/14/2006	16	13.9694
9/14/2006	28	13.9696
9/14/2006	19	13.9700
9/14/2006	14	13.9693
9/14/2006	1	13.9700
9/14/2006	2	13.9250
9/14/2006	59	13.9400
9/14/2006	23	13.9391
9/14/2006	13	13.9400
9/14/2006	12	13.9392
9/14/2006	10	13.9400
9/15/2006	12	13.7275
9/15/2006	35	13.7300
9/15/2006	13	13.7292
9/15/2006	31	13.7294
9/15/2006	29	13.7300
9/15/2006	75	13.6995
9/15/2006	26	13.7000
9/15/2006	86	13.7597
9/15/2006	12	13.7875
9/15/2006	45	13.7900
9/15/2006	39	13.7895
9/15/2006	31	13.7900
9/15/2006	32	13.7594
9/15/2006	6	13.7583
9/15/2006	10	13.7590
9/15/2006	2	13.7550
9/15/2006	17	13.7594
9/15/2006	6	13.7583
9/15/2006	16	13.7594
9/15/2006	7	13.7586
9/15/2006	5	13.7580
9/15/2006	10	13.7590
9/15/2006	6	13.7583
9/15/2006	7	13.7586
9/15/2006	33	13.7594
9/15/2006	67	13.7597



Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/15/2006	78	13.7596
9/15/2006	11	13.7591
9/15/2006	1	13.7500
9/15/2006	5	13.7580
9/15/2006	24	13.7592
9/15/2006	38	13.7595
9/15/2006	6	13.7583
9/15/2006	1	13.7500
9/15/2006	6	13.7600
9/15/2006	11	13.7591
9/15/2006	21	13.7600
9/15/2006	13	13.7592
9/18/2006	11	13.7173
9/18/2006	42	13.7200
9/18/2006	26	13.7196
9/18/2006	26	13.7200
9/18/2006	4	13.6700
9/18/2006	16	13.6694
9/18/2006	42	13.6695
9/18/2006	21	13.6700
9/18/2006	15	13.6693
9/18/2006	2	13.6700
9/18/2006	12	13.6683
9/18/2006	41	13.6700
9/18/2006	14	13.6693
9/18/2006	35	13.6697
9/18/2006	17	13.6700
9/18/2006	14	13.6693
9/18/2006	1	13.6700
9/18/2006	34	13.6688
9/18/2006	19	13.6700
9/18/2006	20	13.6695
9/18/2006	6	13.6700
9/18/2006	18	13.6694
9/18/2006	38	13.6700
9/18/2006	127	13.6697
9/18/2006	27	13.6700
9/18/2006	20	13.6695
9/18/2006	32	13.6697
9/18/2006	5	13.6700
9/18/2006	156	13.6696
9/18/2006	41	13.6698
9/18/2006	9	13.6700

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/18/2006	68	13.6697
9/18/2006	27	13.6696
9/18/2006	62	13.6697
9/18/2006	26	13.6696
9/18/2006	20	13.6695
9/18/2006	40	13.6698
9/18/2006	27	13.6696
9/18/2006	257	13.6697
9/18/2006	10	13.6680
9/18/2006	35	13.6700
9/18/2006	9	13.6689
9/19/2006	12	13.3275
9/19/2006	35	13.3300
9/19/2006	12	13.3292
9/19/2006	30	13.3297
9/19/2006	28	13.3300
9/19/2006	55	13.3295
9/19/2006	30	13.3293
9/19/2006	33	13.3300
9/19/2006	69	13.2696
9/19/2006	9	13.2700
9/19/2006	29	13.2697
9/19/2006	25	13.2700
9/19/2006	18	13.2694
9/19/2006	3	13.2700
9/19/2006	8	13.3400
9/19/2006	15	13.3393
9/19/2006	17	13.3394
9/20/2006	12	13.5883
9/20/2006	34	13.5900
9/20/2006	12	13.5892
9/20/2006	10	13.5900
9/20/2006	24	13.3588
9/20/2006	70	13.3600
9/20/2006	25	13.3596
9/20/2006	19	13.3595
9/20/2006	74	13.3597
9/20/2006	25	13.3600
9/20/2006	16	13.3594
9/20/2006	24	13.3596
9/20/2006	4	13.3600
9/20/2006	2	13.5850
9/20/2006	19	13.5900
9/20/2006	25	13.5888

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/20/2006	14	13.5900
9/20/2006	14	13.5893
9/20/2006	5	13.5900
9/20/2006	12	13.5892
9/20/2006	28	13.5900
9/20/2006	25	13.5896
9/20/2006	11	13.5900
9/20/2006	106	13.5695
9/20/2006	10	13.5700
9/20/2006	11	13.5691
9/20/2006	16	13.5694
9/20/2006	3	13.5700
9/20/2006	58	13.5895
9/20/2006	145	13.5596
9/20/2006	38	13.5595
9/20/2006	19	13.5600
9/20/2006	13	13.5592
9/20/2006	19	13.5595
9/20/2006	5	13.5600
9/20/2006	3	13.5667
9/20/2006	24	13.5696
9/20/2006	8	13.5688
9/20/2006	22	13.5695
9/20/2006	9	13.5689
9/20/2006	7	13.5686
9/20/2006	14	13.5693
9/20/2006	9	13.5689
9/20/2006	10	13.5690
9/20/2006	46	13.5696
9/20/2006	9	13.5689
9/20/2006	93	13.5695
9/20/2006	10	13.5690
9/20/2006	15	13.5893
9/20/2006	16	13.5894
9/20/2006	17	13.5900
9/20/2006	34	13.5894
9/21/2006	27	13.2993
9/21/2006	14	13.3000
9/21/2006	17	13.2994
9/21/2006	5	13.3000
9/21/2006	13	13.2992
9/21/2006	31	13.3000
9/21/2006	15	13.2993

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/21/2006	25	13.4484
9/21/2006	14	13.4500
9/21/2006	17	13.4494
9/21/2006	4	13.4500
9/21/2006	14	13.4493
9/21/2006	29	13.4500
9/21/2006	344	13.4496
9/21/2006	10	13.4500
9/21/2006	16	13.4494
9/21/2006	9	13.4500
9/21/2006	33	13.4497
9/21/2006	51	13.4496
9/21/2006	10	13.4500
9/21/2006	14	13.2486
9/21/2006	31	13.2500
9/21/2006	41	13.2495
9/21/2006	141	13.2496
9/22/2006	3	12.9933
9/22/2006	44	13.0000
9/22/2006	27	12.9996
9/22/2006	12	13.0175
9/22/2006	47	13.0200
9/22/2006	33	13.0197
9/22/2006	28	13.0200
9/22/2006	28	12.9993
9/22/2006	17	13.0000
9/22/2006	14	12.9993
9/25/2006	34	12.9294
9/25/2006	15	12.9300
9/25/2006	14	12.9293
9/25/2006	3	12.9300
9/25/2006	25	12.9488
9/25/2006	14	12.9500
9/25/2006	13	12.9492
9/25/2006	44	12.9500
9/25/2006	25	12.9496
9/25/2006	62	12.9495
9/25/2006	21	12.9500
9/25/2006	14	12.9493
9/25/2006	20	12.9495
9/25/2006	4	12.9500
9/26/2006	3	13.5167
9/26/2006	7	13.5200
9/26/2006	14	13.5193

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/26/2006	36	13.5194
9/26/2006	29	13.5200
9/26/2006	3	13.5467
9/26/2006	27	13.5500
9/26/2006	12	13.5492
9/26/2006	31	13.5494
9/26/2006	3	13.5500
9/26/2006	11	13.2964
9/26/2006	40	13.3000
9/26/2006	27	13.2996
9/26/2006	24	13.3000
9/26/2006	13	13.5177
9/26/2006	36	13.5200
9/26/2006	12	13.5192
9/26/2006	33	13.5194
9/26/2006	31	13.5200
9/27/2006	12	13.5775
9/27/2006	47	13.5800
9/27/2006	31	13.5797
9/27/2006	29	13.5800
9/27/2006	5	13.5780
9/27/2006	6	13.5800
9/27/2006	14	13.5793
9/27/2006	21	13.5800
9/27/2006	52	13.5494
9/27/2006	21	13.5500
9/27/2006	14	13.5493
9/27/2006	21	13.5495
9/27/2006	4	13.5500
9/27/2006	9	13.5978
9/27/2006	30	13.6000
9/27/2006	23	13.5996
9/27/2006	6	13.6000
9/27/2006	18	13.5483
9/27/2006	9	13.5500
9/27/2006	12	13.5492
9/27/2006	32	13.5500
9/27/2006	18	13.5494
9/27/2006	48	13.5496
9/27/2006	24	13.5500
9/27/2006	18	13.5494
9/27/2006	2	13.5500
9/27/2006	22	13.5600

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

9/27/2006	31	13.5597
9/27/2006	20	13.5595
9/27/2006	255	13.5596
9/28/2006	69	13.4696
9/28/2006	32	13.4694
9/28/2006	29	13.4697
9/28/2006	2	13.4700
9/28/2006	52	13.4994
9/28/2006	14	13.4993
9/28/2006	16	13.5000
9/28/2006	11	13.4991
9/28/2006	7	13.5000
9/28/2006	13	13.4992
9/28/2006	6	13.4583
9/28/2006	1	13.4600
9/28/2006	10	13.4590
9/28/2006	8	13.4600
9/28/2006	31	13.4994
9/28/2006	11	13.4582
9/28/2006	32	13.4600
9/29/2006	15	13.3080
9/29/2006	37	13.3100
9/29/2006	30	13.3093
9/29/2006	10	13.3100
9/29/2006	13	13.3085
9/29/2006	20	13.3100
9/29/2006	19	13.3089
9/29/2006	35	13.3100
9/29/2006	16	13.3094
9/29/2006	20	13.3095
9/29/2006	17	13.3094
10/2/2006	18	12.8894
10/2/2006	13	12.9192
10/2/2006	10	12.9200
10/2/2006	24	12.9192
10/2/2006	14	12.9200
10/2/2006	12	12.9192
10/2/2006	5	12.9200
10/2/2006	11	12.9191
10/2/2006	20	12.9200
10/3/2006	11	12.8773
10/3/2006	42	12.8800
10/3/2006	26	12.8796
10/3/2006	26	12.8800

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

CUSIP No. M8737E108

10/3/2006	3	12.9033
10/3/2006	29	12.9100
10/3/2006	12	12.9092
10/3/2006	27	12.9096
10/3/2006	24	12.9100
10/3/2006	3	12.8800
10/3/2006	13	12.8792
10/3/2006	3	12.8800
10/3/2006	25	12.8796
10/3/2006	8	12.8800
10/3/2006	22	12.8795
10/3/2006	3	12.8800
10/3/2006	19	12.8795
10/3/2006	2	12.8550
10/3/2006	23	12.8600
10/3/2006	12	12.8592
10/3/2006	14	12.8593
10/3/2006	10	12.8600
10/4/2006	24	12.6596
10/4/2006	58	12.4495
10/4/2006	29	12.5693
10/4/2006	16	12.5700
10/4/2006	16	12.5694
10/4/2006	16	12.5700
10/4/2006	13	12.5792
10/4/2006	7	12.5800
10/4/2006	8	12.5788
10/4/2006	1	12.5800
10/4/2006	57	12.6395
10/4/2006	27	12.6396
10/4/2006	25	12.6400
10/4/2006	51	12.5594
10/4/2006	25	12.5596
10/4/2006	23	12.5600
10/4/2006	19	12.4584
10/4/2006	53	12.4600
10/4/2006	19	12.4595
10/4/2006	112	12.4597
10/4/2006	37	12.4600
10/4/2006	23	12.4596
10/4/2006	4	12.4600
10/4/2006	43	12.4495
10/4/2006	9	12.4489
10/4/2006	13	12.4492
10/4/2006	2	12.4450
10/4/2006	23	12.4496
10/4/2006	9	12.4489
10/4/2006	20	12.4495
10/4/2006	8	12.4488
10/4/2006	7	12.4486
10/4/2006	148	12.4496
10/4/2006	10	12.4490
10/4/2006	1	12.4400

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form SC 13D/A

10/4/2006	5	12.4480
10/4/2006	20	12.4495
10/4/2006	30	12.4493
10/4/2006	6	12.4483
10/4/2006	20	12.6380
10/4/2006	59	12.6400
10/4/2006	20	12.6395
10/4/2006	52	12.6396
10/4/2006	30	12.6400
10/4/2006	17	12.6394
10/4/2006	3	12.6400